Frequency of Early-Stage Lymphedema and Risk Factors in Postoperative Patients with Breast Cancer

Aykut Soyder¹, Engin Taştaban², Serdar Özbaş³, Şükrü Boylu¹, Hedef Özgün¹

¹Department of General Surgery, Adnan Menderes University Faculty of Medicine, Aydın, Turkey

²Department of Physical Therapy and Rehabilitation, Adnan Menderes University Faculty of Medicine, Aydın, Turkey

³Department of General Surgery, Güven Hospital, Ankara, Turkey

ABSTRACT

Objective: Lymphedema is a chronic major complication that is seen frequently post-operatively and has negative effects on quality of life. In our study, determining the early-stage postoperative lymphedema frequency and specifying the risk factors in its development has been aimed.

Materials and Methods: One hundred one cases that were operated on for breast cancer were evaluated regarding the 12-month control of their clinical specifications, histopathological specifications, and specifications related with the surgical intervention retrospectively. The data related to the parameters envisioned as risk factors were evaluated.

Results: Lymphedema development was found in 7 (6.9%) out of 101 cases constituting the study group. No significant difference ($p>0.05$) in terms of lymphedema development was determined among age, body mass index (BMI), chemotherapy (CT), postoperative seroma or infection, mastectomy with the dominant arm, and breast-conserving surgery (BCS), which were evaluated as risk factors. There was a significance ($p<0.05$) between the other risk factors, which were axillary dissection (AD), number of positive lymph nodes (LN), radiotherapy (RT), the tumor size (T), and lymphedema existence. In every case in which lymphedema was determined, it was seen that there was axillary LN involvement and $15\leq\text{LN}$ were ablated in the dissection ($p<0.05$).

Conclusion: It is seen that AD, RT applied to the breast cancer patients, and T are important risk factors in early-stage lymphedema development. No early-stage lymphedema development was determined in any of the patients to whom sentinel lymph node dissection (SLND) was applied.

Key words: Lymphedema, breast cancer, risk factors, incidence

Introduction

The increase in the survival time of breast cancer cases in the last 2 decades has brought health problems in the long term relating to treatment (1). Lymphedema development, which affects the quality of life negatively, is defined as interstitial tissue effusion rich in protein as a result of failure in the lymphatic system in patients who undergo surgical treatment and radiotherapy (RT) for breast cancer (2). Even though the lymphedema development rates are given as 30% in the literature, there are many studies which that it in a large range of 2%-83% (3-5). This large range difference is thought to depend on the technique of lymphedema measurement, differences in description, and the timing of the assessment. Lymphedema development is frequently seen during the first 18 months but sometimes weeks or years after the treatment (6, 7). As the presence of lymphedema prevents daily activities, it affects the patient psychologically, socially, and economically, as well (8). Lymphedema is considered to be an important complication of breast cancer surgery that comes into prominence, as information towards preventing its development is limited; its treatment is difficult, it is progressive, and it affects a patient's quality of life negatively. Many risk factors are mentioned in the development of lymphedema. Determining these parameters will help the determination of high-risk case groups, thus providing the preventive precautions to be applied. There are 3 basic subjects that are envisioned as risk factors in lymphedema development; these are the factors relating to the treatment, the disease, and the patient (9-11). The factors relating to the disease are the stage of the tumor (T), the number of lymph nodes (LN) dissected, and the localization of the T. The factors relating to the treatment include the type of the applied surgical treatment and other treatment combinations applied together with RT and chemotherapy (CT). The factors relating to the patient are age, body mass index (BMI), wound site infection, and excessive use of extremity. Even though the factors that might be related to arm lymphedema development in patients with breast cancer have been assessed in many studies, its etiology has not been fully understood yet.

In our study, we aimed to determine the rate of lymphedema development in cases to whom surgical intervention was applied in our clinic due to breast cancer to assess the risk factors and differentiate the case groups with high risk of lymphedema development.

This study was presented as a poster at the 18th National Surgical Congress, 23-27 May 2012, İzmir, Turkey.

Address for Correspondence:

Aykut Soyder, Department of General Surgery, Adnan Menderes University Faculty of Medicine, Aydın, Turkey

Phone: +90 256 444 12 56 e-mail: asoyder@yahoo.com

Received: 09.12.2013

Accepted: 27.01.2014

Materials and Methods

One hundred one female patients diagnosed with one-sided breast cancer who had surgical intervention to the breast and axilla between January 2010-March 2011 were included in the study. In the routine follow-up of the cases, the clinical and histopathological data and the data relating to the surgical procedure assessed at the 12th month were examined retrospectively, and arm measurements were made for lymphedema evaluation. Among the factors relating to the patient envisioned as risk factors, age (<50 or ≥50), BMI (<25 kg/m², ≥25 kg/m²), smoking status, arm dominance (present or not), the surgery of breast [mastectomy/breast-conserving surgery (BCS) and axilla (axillary dissection (AD)/sentinel lymph node dissection (SLND)] applied, dissected number of LN, LN positivity, postoperative seroma and infection development (present or not), CT or RT treatment, grade (1, 2, 3) relating to the T₁, T₂, T₃, and parameters of histopathological type were evaluated (Table 1).

Arm Lymphedema Measurement Method

The circumferential measurement method was used. Circumferential measurements were made in four regions of both upper extremities: the metacarpophalangeal joint, wrist, and 10 cm distal and 15 cm proximal to the lateral epicondyle. A diameter difference of more than 2 cm in the measurements made at the four regions compared to the healthy side was evaluated as lymphedema presence (12).

All of the cases were informed of lymphedema and protective measures after the clinical evaluation. The cases in which lymphedema development was determined were taken into a treatment program by the Physical Treatment and Rehabilitation Clinic, and written informed consent was obtained from patients who participated in this study.

Statistical Analysis

The SPSS-17.0 statistical software package was used. Statistical evaluation of the data was performed using Pearson chi-square test and Mann-Whitney test. $p < 0.05$ was considered statistically significant. Age and BMI values of the cases were shown as mean ± SD (minimum-maximum).

Results

Age, BMI, smoking status, and arm dominance, which were considered as the risk factors of the cases, were examined: the mean age of 101 cases was 52 ± 10 (32-76), whereas it was 51 ± 12.9 (38-68) in 7 cases (6.9%) where lymphedema was found. Lymphedema was found in 4 out of 50 cases aged under 50 and 3 out of 51 cases aged over 50 ($p: 0.706$). BMI evaluation of all cases showed a mean value of 28.9 ± 4 (20.9-42.5); 17 cases had a BMI value under 25, and 84 cases had a value of 25 and over. Lymphedema was found in 1 case whose BMI value was under 25 and in 6 cases whose BMI values were over 25 ($p: 1.000$). In the whole study group, 5 cases (4.9%) were smokers, but none of the 7 cases in which lymphedema development was found was a smoker. Arm dominance was present in 3 out of 7 cases (42.9%) ($p: 0.699$).

When the factors relating to the applied treatment, such as the surgery of the breast (mastectomy/BCS) and axilla (AD/SLND), dissected number of LN, number of positive LN, postoperative seroma or infection development, and RT and CT treatments, were examined, lymphedema development was found in 4 (57.1%) cases to which mastectomy was applied and in 3 cases (42.9%) to which BCS was applied ($p: 0.102$). It was seen that AD was performed in every case

in which lymphedema development was found ($p: 0.040$) and that there was no lymphedema development in patients to whom SLND was applied ($p: 0.014$). In every case to which AD was applied and lymphedema development was found, it was seen that the number of LN excised was ≥15 ($p: 0.013$). The number of LN dissected in every case to which AD was applied was 15 (9-24) and 28 (22-34) in the cases in which lymphedema was found ($p: 0.069$). When the positivity of the dissected LN was evaluated, the positive LN number in the whole case group was 1 (0-5) but 8 (7-26) in the lymphedema group ($p: 0.019$). Lymphedema development was found in 3 (9%) out of 33 (32.7%) cases in which postoperative seroma developed ($p: 0.680$) and 1 (16.6%) out of 6 (5.9%) cases in which infection developed ($p: 1.000$). It was seen that every case in which lymphedema was seen had RT ($p: 0.041$) and CT ($p: 1.000$) treatment.

When the factors relating to the disease, such as the T grade, T value, and parameters of T histopathology, were assessed as the risk factors relating to the disease, it was seen that the T grade was 2 in all cases in the lymphedema group. T₁ was determined in 2 (28.6%), T₂ was determined in 3 (42.9%), and T₃ was determined in 2 (28.6%) of the cases in which lymphedema was found ($p: 0.025$). As for T histopathology, invasive ductal carcinoma was seen in 6 (85.7%) and inflammatory carcinoma was seen in 1 (14.3%) case in the group with lymphedema.

Discussion and Conclusions

Breast cancer is among the most frequent cancer types seen in women, and its frequency has shown an upward inclination in recent years (13, 14). When cancer data of the Ministry of Health in Turkey were examined, it was seen that the frequency of breast cancer in 2006 was 37.6 per 100,000, while it became 38.5 in 2007 and 41.6 in 2008 (15). Besides the increasing frequency of breast cancer, the survival time has lengthened significantly through the current early diagnosis methods for breast cancer and multidisciplinary treatment approaches, while the problems affecting the quality of life negatively have been encountered more frequently. Of these problems, lymphedema differs from others, as it is seen frequently in the long term during the postoperative period.

The most important reason of such a large range of lymphedema incidence is the timing differences in detection and evaluation (16). In the evaluation of lymphedema, volumetric measurement, circumferential measurement, tissue tonometer, or imaging techniques are used. While it is known that volumetric measurement techniques give more accurate results, the circumferential measurement technique is used more frequently because of its higher practicability (17). For this reason, we used the circumferential measurement technique in our study. The 6th postoperative month is envisioned as the best time for the evaluation, when the adjuvant CT and RT are usually completed and the lymphedema symptoms became measurable (18). In our study, lymphedema development was found in 7 (6.9%) cases at the assessment at the 12th month.

When the risk factors were assessed in patients with lymphedema development, no statistically significant difference was found between the cases aged over 50 and under 50 in terms of lymphedema development ($p: 0.706$). Geller et al. (9) reported a significant increase in lymphedema development risk in women aged under 50. In many studies where age is assessed in the literature, similar to the results we obtained, this factor did not show a significant effect on lymphedema development (5, 7, 9, 11, 19).

When BMI was assessed as a risk factor, it was seen that there was no statistically significant difference between the BMI values of >25 or ≤ 25 on lymphedema development ($p:1.000$). In the studies, lymphedema development risk shows a 2-fold increase in cases where BMI is over 30. Even though its etiology is unclear, it is thought to occur because of increased fat and the subcutaneous tissue's role as a lymphatic

fluid resource or the increase in lymphatic damage as a result of the need for more ecartation in axillary intervention (20).

In many studies present in the literature where smoking status and arm dominance are assessed, they are not found to be potent risk factors in lymphedema development, similar to our findings (7, 21, 22).

Table 1. The distribution of parameters in the case groups

Risk Factors	All case groups (n:101) %	Lymphedema (+) group (n:7) %	p value
Age	52±10 (32-76)	51±12.9 (38-68)	0.756
• 50>	50 (49.5%)	4 (57.1%)	
• 50≤	51 (50.5%)	3 (42.9%)	
BMI	28.9±4 (20.9-42.5)	30.4±5 (24.21-35.98)	1.000
• 25>	17 (16.8%)	1 (14.3%)	
• 25≤	84 (83.2%)	6 (85.7%)	
Smoking status	5 (4.9%)	0	0.699
Arm dominance	55 (54.5%)	3 (42.9%)	
Mastectomy/BCS			
• Mastectomy	29 (28.7%)	4 (57.1%)	0.102
• BCS	72 (71.3%)	3 (42.9%)	
AD/SLND			
• AD	54 (53.5%)	7 (100%)	0.040
• SLND	47 (46.5%)	0	0.014
The number of LN dissected in cases to whom AD has been applied	15 (9-24)	28 (22-34)	0.069
LN positivity	1(0-5)	8 (7-26)	0.019
Cases with 15≤LN dissection	51 (50.5%)	7 (100%)	0.013
Seroma development	33 (32.7%)	3(42.9%)	0.680
Infection development	6 (5.9%)	1 (14.3%)	1.000
RT treatment (+)	62 (61.4%)	7 (100%)	0.041
CT treatment (+)	92 (91.1%)	7 (100%)	1.000
Tumor			0.025
• Grade			
1	5 (4.9%)	7 (100%)	
2	89 (88.1%)		
3	7 (6.9%)		
• Size (T)			
T1	25 (24.8%)	2 (28.6%)	
T2	71 (70.3%)	3 (42.9%)	
T3	5 (4.9%)	2 (28.6%)	
• Histopathological type			
• Invasive ductal carcinoma	85 (84.1%)	6 (85.7%)	
Tubular carcinoma	3 (2.9%)	0	
Papillary carcinoma	3 (2.9%)	0	
Medullary carcinoma	2 (1.9%)	0	
Invasive lobular carcinoma	2 (1.9%)	0	
Apocrine carcinoma	3 (2.9%)	0	
Inflammatory carcinoma	2 (1.9%)	1 (14.3%)	

BMI: Body mass index; BCS: breast-conserving surgery; AD: axillary dissection; SLND: sentinel lymph node dissection; LN: lymph node; RT: radiotherapy; CT: chemotherapy

Table 2. Studies reporting the prevalence of lymphedema following different surgical interventions in the literature

Study	Applied Surgical Procedure	Lymphedema Definition	Follow-up Period (month)	Number of cases	Incidence of lymphedema (%)
Kissin et al. (30)	Unidentified	≥ 2 cm	9	200	25.5
Werner et al. (20)	AD, RT	≥ 2.5 cm	37	282	19.5
Lin et al. (31)	RM, MRM, SM + AD, and RT	≥ 2 cm	24	283	16
Keramopoulos et al. (32)	SM/MRM + AD	≥ 2 cm	6	104	17
Deutsch et al. (33)	RM/Mastectomy+ RT Only Mastectomy	≥ 2 cm	36	1665	46.3
Clark et al. (5)	Mastectomy/SM	PVD $\geq 20\%$ aPVD _{change} $\geq 5\%$	36	188	20.7
Wilke (29)	SLND	> 2 cm	6	2904	7
Lucci (35)	SLND	≥ 2 cm	12	411	6
Langer (34)	SLND	> 2 cm	31 (average)	431	3,5
McLaughlin et al. (36)	SLND	> 2 cm	60 (average)	600	5

MRM: Modified radical mastectomy; PVD: volume difference ratio; RM: radical mastectomy; RT: radiotherapy; SM: segmental mastectomy; AD: axillary dissection; SLND: sentinel lymph node dissection

It is reported that the range of surgery of the breast and axilla and adjuvant treatments, such as RT, may increase the risk of lymphedema (23). Schunemann and Willich et al. (24) reported lymphedema development rates after radical mastectomy without postoperative RT, modified radical mastectomy (MRM), and BCS of 22.3%, 19.1%, and 6.7%, respectively. In most of the studies in the literature, it is reported that there is a relation between AD range and lymphedema incidence. Siegel et al. (25) reported that the lymphedema incidence of 37% with level I, II, and III dissection reduces to 8% when only level I and II dissection is applied. Moreover, in a study where BCS was applied, the lymphedema rate of 15% in the cases in which lumpectomy and AD were performed reduced to 3% in cases with only lumpectomy (26). In many studies, the LN number dissected was found to increase the lymphedema risk (18, 27, 28). It is reported that the lymphedema frequency is 5-7 times less in SLND, which is recommended to be performed in axilla-negative cases today compared to AD (29-36).

When different procedures for breast cancer, such as mastectomy, RT, and axillary procedures (AD/SLND), were assessed in terms of lymphedema development, it was seen that lymphedema rates varied between 16% and 46.3% during a follow-up period of 6 to 37 months, but in the last few years, it has also been seen in studies examining the cases to which SLND is applied that the lymphedema incidence is far lower, such as 3.5%-7% (Table 2). In our study, even though no statistically significant difference was seen between the cases to which mastectomy and BCS were applied ($p:0.102$), it was found that AD was applied to every case where lymphedema had developed, and no lymphedema development was found in any case in the early-stage cases ($p:0.014$). When the dissected LN number in the cases to which AD was applied was assessed, it was seen that the lymphedema incidence increased with increasing LN number dissected ($p:0.069$) and LN positivity ($p:0.019$).

In our study, RT treatment seemed to be one of the major factors that increased the lymphedema incidence ($p:0.041$). In the literature, even cases without surgical intervention with RT to the axilla showed increased lymphedema incidence; moreover, with the combination of AD, it is reported to increase the lymphedema risk even more by

showing a synergistic effect (37). In similar studies, the lymphedema incidence in patients to whom RT was applied in addition to surgery was 41%, while this ratio was 17% in patients in whom surgery was performed alone (38, 39).

It is reported in the literature that infection and seroma development with adjuvant CT treatment do not increase the lymphedema incidence. No significant difference in these parameters in terms of lymphedema development was found in our study ($p>0.05$).

In all 7 (6.9%) cases in which lymphedema development was found, the T grade was 2. T histopathology revealed invasive ductal carcinoma in 6 (85.7%) cases and inflammatory carcinoma in 1 (14.3%) case.

When the relationship between the T value and lymphedema incidence was assessed, T₁ was seen in 2 (28.6%), T₂ was determined in 3 (42.9%), and T₃ was determined in 2 (28.6%) cases. When compared to the whole case group, a significant difference was determined between T size and lymphedema incidence ($p: 0.025$). In many studies, T diameter was found to be a potent factor in lymphedema development (7, 40, 41).

As a result, a statistically significant relationship has been determined with the range of the AD ($15 \leq$ LN), dissected positive LN number, RT, and T and early-stage lymphedema incidence ($p<0.05$). The widespread prevalence of cases with early-stage breast cancer diagnosis, small T sizes, and absence of application of RT to the axilla (as the axillary involvement is lower), as well as the routine preference of SLND in cases where the axilla is clinically negative, are the basic reasons of the low lymphedema rates in our study group.

We do not have enough of a sample size to compare the groups based on the variables and no preoperative baseline measurements.

Ethics Committee Approval: N/A.

Conflict of Interest: No conflict of interest was declared by the authors.

Peer-review: Externally peer-reviewed.

Informed Consent: Written informed consent was obtained from patients who participated in this study.

Author Contributions: Concept - A.S.; Design - A.S., S.Ö.; Supervision - S.Ö., H.Ö.; Funding - A.S., E.T.; Materials - A.S., E.T.; Data Collection and/or Processing - A.S., E.T.; Analysis and/or Interpretation - A.S., E.T.; Literature Review - A.S., S.Ö., H.Ö.; Writer - A.S.; Critical Review - Ş.B.; Other - Ş.B.

Financial Disclosure: The authors declared that this study has received no financial support.

References

- American Cancer Society. Available from: URL: <http://www.cancer.org/>
- Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma associated lymphedema. *Cancer* 2002; 95:2260-2267. (PMID: 12436430) [CrossRef]
- Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. *J Natl Cancer Inst* 2001; 93:96-111. (PMID: 11208879) [CrossRef]
- Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. *Cancer* 1998; 83:2776-2781. (PMID: 9874397) [CrossRef]
- Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: A three-year follow-up study. *QJM* 2005; 98:343-348. (PMID: 15820971) [CrossRef]
- Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. *Cancer* 2001; 92:1368-1377. (PMID: 11745212) [CrossRef]
- Edwards TL. Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. *Aust N Z J Surg* 2000; 70:412-418. (PMID: 10843395) [CrossRef]
- Kebudi A, Uludağ M, Yetkin G, Citgez B, İşgor A. Lymphedema after modified radical mastectomy for the breast cancer: Incidence and risk factors. *J Breast Health* 2005; 1:1-5.
- Galler BM, Vacek PM, O'Brain P, Secker-Walker RH. Factors associated with arm swelling after breast cancer surgery. *J Women's Health* 2003; 12:921-930. (PMID: 14670172) [CrossRef]
- Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR. Breast cancer related lymphedema: What are the significant predictors and how they affect the severity of lymphedema? *Breast J* 2006; 6:536-543. (PMID: 17238983) [CrossRef]
- Coen JJ, Taghian AG, Kachnic LA, Assaag SI, Powell SN. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. *Int J Radiat Oncol Biol Phys* 2003; 55:1209-1215. (PMID: 12654429) [CrossRef]
- Gerber LH. A review of measures of lymphedema. *Cancer* 1998; 83:2803-2804. (PMID: 9874401) [CrossRef]
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55:74-108. (PMID: 15761078) [CrossRef]
- Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. *Int J Cancer* 2006; 119:2417-2422. (PMID: 16964611) [CrossRef]
- The Ministry of Health of Turkey. Health statistics yearbook 2010. Available from: URL: <http://www.saglik.gov.tr>
- Park JH, Lee WH, Chung HS. J. Incidence and risk factors of breast cancer lymphoedema. *Clin Nurs* 2008; 17:1450-1459. (PMID: 18482142) [CrossRef]
- Morrell RM, Halyard MY, Schild SE, Ali MS, Gunderson LL, Pockaj BA. Breast cancer-related lymphedema. *Mayo Clin Proc* 2005; 80:1480-1484. (PMID: 16295027) [CrossRef]
- Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema following breast cancer: Incidence, risk factors, and effect on upper-body function. *J Clin Oncol* 2008; 26:3536-3542. (PMID: 18640935) [CrossRef]
- Deo SV, Ray S, Rath GK, Shukla NK, Kar M, Asthana S, Raina V. Prevalence and risk factors for development of lymphedema following breast cancer treatment. *Indian J Cancer* 2004; 41:8-12. (PMID: 15105573)
- Werner RS, McKormick B, Petrek J, Cox L, Cirrincione C, Gray JR, Yahalom J. Arm edema in conservatively managed breast cancer. *Radiology* 1991; 180:177-184. (PMID: 2052688)
- Querci della Rovere G, Ahmad I, Singh P, Ashley S, Daniels IR, Mortimer P. An audit of the incidence of arm lymphoedema after prophylactic level I/II axillary dissection without division of the pectoralis minor muscle. *Ann R Coll Surg Engl* 2003; 85:158-161. (PMID: 12831486) [CrossRef]
- Arrault M, Vignes S. Risk factors for developing upper limb lymphoedema after breast cancer treatment. *Bull Cancer* 2006; 93:1001-1006. (PMID: 17074659)
- Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. *Cancer* 2001; 92:1783-1787. (PMID: 11745250) [CrossRef]
- Schunemann H, Willich N. Lymphedema after breast carcinoma. A study of 5868 cases. *Dtsch Med Wochenschr* 1997; 122:536-541. (PMID: 9190300)
- Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients. *Arch Surg* 1990; 125:1144-1147. (PMID: 2400307) [CrossRef]
- Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. *Ann Surg Oncol* 2002; 9:543-549. (PMID: 12095969) [CrossRef]
- Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. *Arch Surg* 2003; 138:482-487. (PMID: 12742949) [CrossRef]
- Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME, Voogd AC. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. *Eur J Surg Oncol* 2003; 29:341-350. (PMID: 12711287) [CrossRef]
- Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial. *Ann Surg Oncol* 2006; 13:491-500. (PMID: 16514477) [CrossRef]
- Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. *Br J Surg* 1986; 73:580-584. (PMID: 3730795) [CrossRef]
- Lin PP, Alison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, Baker RR. Impact of axillary lymph node dissection on the therapy of breast cancer patients. *J Clin Oncol* 1993; 11:1536-1544. (PMID: 8336192)
- Keramapoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: A multivariate approach. *Oncology* 1993; 50:445-449. (PMID: 8233285) [CrossRef]
- Deutsch M, Flickinger C. Arm edema after lumpectomy and breast irradiation. *Am J Clin Oncol* 2003; 26:229-231. (PMID: 12796589) [CrossRef]
- Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: A prospective Swiss multicenter study on 659 patients. *Ann Surg* 2007; 245:452-461. (PMID: 17435553) [CrossRef]
- Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencanz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. *J Clin Oncol* 2007; 25:3657-3663. (PMID: 17485711) [CrossRef]

36. McLaughlin S, Wright M, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Patient perceptions and precautionary behaviors. *J Clin Oncol* 2008; 26:5220-5226. (PMID: 18838708) [\[CrossRef\]](#)
37. Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. *Surg Oncol* 2006; 15:153-165. (PMID: 17187979) [\[CrossRef\]](#)
38. Moffat FL Jr, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: some is good, but all is better. *J Surg Oncol* 1992; 51:8-13. (PMID: 1518298) [\[CrossRef\]](#)
39. Ozaslan C, Kuru B. Lymphedema after treatment of breast cancer. *Am J Surg* 2004; 187:69-72. (PMID: 14706589) [\[CrossRef\]](#)
40. Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. *Cancer* 2001; 92:1783-1787. (PMID: 11745250) [\[CrossRef\]](#)
41. Goffman TE, Laronga C, Wilson L, Elkins D. Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery. *Breast J* 2004; 10:405-411. (PMID: 15327493) [\[CrossRef\]](#)